A useful treatment for patients with advanced mixed-type small cell neuroendocrine carcinoma of the prostate: A case report

Oncology Letters

Volumn 5, Issue 3, 2013, Pages 793-796

  Uemura, Kei Ichiro ^a   Nakagawa, Go ^a   Chikui, Katsuaki ^a   Moriya, Fukuko ^a   Nakiri, Makoto ^a   Hayashi, Tokumasa ^a   Suekane, Shigetaka ^a   Matsuoka, Kei ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

External beam radiotherapy with intra arterial chemotherapy; Ischuria; Locally advanced tumor; Prostatic small cell neuroendocrine carcinoma

Indexed keywords

BICALUTAMIDE; CISPLATIN; GOSERELIN; IFOSFAMIDE; PROSTATE SPECIFIC ANTIGEN; SYNAPTOPHYSIN;

AGED; ANDROGEN THERAPY; ARTICLE; BIOPSY; BONE METASTASIS; CASE REPORT; DYSURIA; EXTERNAL BEAM RADIOTHERAPY; HEMATURIA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; PROSTATE CARCINOMA; SMALL CELL NEUROENDOCRINE CARCINOMA; URETHRAL CATHETER; URINARY TRACT OBSTRUCTION; URINE RETENTION;

EID: 84872729218     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1136     Document Type: Article

References (18)

1. Palmgren JS, Karavadia SS and Wakefield MR: Unusual and underappreciated: small cell carcinoma of the prostate. Semin Oncol 34: 22-29, 2007.
2. Yao JL, Huang J and di Sant'Agnese PA: Small cell carcinoma of the prostate. Diagn Histopathol 14: 117-121, 2008.
3. Haider K, Shahid RK, Finch D, et al: Extra pulmonary small cell carcinoma: a Canadian province's experience. Cancer 107: 2262-2269, 2006.
4. Levenson RM Jr, Ihde DC, Matthews MJ, Cohen MH, GazdarAF, Bunn PA Jr and Minna JD: Small cell carcinoma presenting as an extrapulmonary neoplasm: sites of origin and response to chemotherapy. J Natl Cancer Inst 67: 607-612, 1981.
5. Remic SC and Ruckdeschel JC: Extrapulmonary and pulmonary small-cell carcinoma: tumor biology, therapy, and outcome. Med Pediatr Oncol 20: 89-99, 1992.
6. Tanaka M, Suzuki Y, Takaoka K, Suzuki N, Murakami S, Matsuzaki O and Shimazaki J: Progression of prostate cancer to neuroendocrine cell tumor. Int J Urol 8: 431-436, 2001.
7. Oesterling JE, Hauzeur CG and Farrow GM: Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients. J Urol 147: 804-807, 1992.
8. Papandreou CN, Daliani DD, Thall PF, et al: Result of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 20: 3072-3080, 2002.
9. Di Sant'Agnese PA and Cockett AT: The prostatic endocrine-paracrine (neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: a review and future directions in basic research. J Urol 152: 1927-1931, 1994.
10. Deorah S, Rao MB, Raman R, Gaitonde K and DonovanJF: Survival of patients with small cell carcinoma of the prostate during 1973-2003: a population-based study. BJU Int 109: 824-830, 2012.
11. Spiess PE, Pettaway CA, Vakar-Lopez F, et al: Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer 110: 1729-1737, 2007.
12. Yao JL, Mardeb R and Bourne P: Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol 30: 705-712, 2006.
13. van Meerbeeck JP, Fennell DA and De Ruysscher DK: Small-cell lung cancer. Lancet 378: 1741-1755, 2011.
14. Uemura K, Nishihara K, Hayashi T, Tomiyasu K and Matsuoka K: Improvement in urinary retention due to recurrent anastomotic prostate cancer treated with various therapies by intra-arterial infusion of cisplatin and ifosfamide. J Infect Chemother 18: 753-755, 2012.
15. Früh M, Kacsir B, Ess S, Cerny T, Rodriguez R and Plassnilm L: Extrapulmonary small cell carcinoma: an indication for prophylactic cranial irradiation? A single center experience. Strahlenther Onkol 187: 561-567, 2011.
16. Walenkamp AM, Sonke GS and Sleijfer DT: Clinical and therapeutic aspects of extrapulmonary small cell carcinoma. Cancer Treat Rev 35: 228-236, 2009.
17. Vashchenko N and Abrahamsson PA: Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 47: 147-155, 2005.
18. Feng S, Agoulnik IU, Truong A, et al: Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocr Relat Cancer 17: 1021-1033, 2010.